Evaxion Biotech A/S ADR EVAX 深 滬
已收盤 12-24 16:00:00 美东时间
4.92
+0.190
+4.02%
華盛通- 最 高5.00
- 今 開4.70
- 成交量 2.30万股
- 最 低 4.70
- 昨 收 4.73
- 總市值 4103.38万
- 52周最高 12.1499
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.20
- 委 比 -79.53%
- 總股本 834.02万
- 歷史最高 1252.00
- 量 比 0.15
- 振 幅 6.34%
- 歷史最低 4.025
- 每 手 1
- 風險率 1.70%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out
Merck declines its option on Evaxion's EVX-B2 gonorrhea vaccine, leaving global rights with Evaxion and no change to its cash runway through 2027.
12-20 01:43
Reported Saturday, Evaxion Announces EVX-04 Triggers Specific Immune Responses Across 16 Selected ERV Fragments And Supports Broad Tumor Coverage For Acute Myeloid Leukemia
Designed with our proprietary AI-Immunology™ platform based on patient sequencing data, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigensEVX-04 induces targeted immune responses
12-08 16:49
Evaxion Advances Multi-Component Cytomegalovirus Vaccine Program, EVX-V1, With New Data Demonstrating Protective Effects Of Lead Antigens
Evaxion's AI-Immunology™ platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models EVX-V1 is a next-generation, multi-component vaccine program combining these
11-20 21:04
Evaxion Biotech Increases Share Capital Following Warrant Exercise
Evaxion Biotech ( ($EVAX) ) has shared an announcement. On November 4, 2025, Ev...
11-19 00:27
Evaxion A/S Announces 2026 Financial Calendar
Evaxion Biotech ( ($EVAX) ) has shared an announcement. On November 12, 2025, E...
11-12 21:52
Evaxion Announces New Data Exploring Immune Responses Following Treatment With AI-designed Personalized Cancer Vaccine EVX-01
Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new data exploring immune responses following treatment with
11-08 06:16
Evaxion Biotech Q3 EPS $0.01 Beats $(0.21) Estimate, Sales $7.492M Beat $2.500M Estimate
Evaxion Biotech (NASDAQ:EVAX) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.21) by 104.76 percent. This is a 125 percent increase over losses of $(0.04) per share from
11-06 20:32
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
What's Next: Evaxion Biotech's Earnings Preview
Evaxion Biotech (NASDAQ:EVAX) is set to give its latest quarterly earnings repo...
11-06 04:02
Evaxion Unveils AI-Designed Cancer Vaccine Candidate EVX-04
Evaxion Biotech ( ($EVAX) ) has shared an update. On November 3, 2025, Evaxion ...
11-03 22:48
